Last reviewed · How we verify
Methemoglobinemia — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Methylthioninium | Methylthioninium | Shandong Cancer Hospital and Institute | Microtubule-associated protein tau, Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Methemoglobinemia
- Shandong Cancer Hospital and Institute · 1 drug in Methemoglobinemia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Methemoglobinemia:
- Methemoglobinemia treatment updates — RSS
- Methemoglobinemia treatment updates — Atom
- Methemoglobinemia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Methemoglobinemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/methemoglobinemia. Accessed 2026-06-10.
Related
- Methemoglobinemia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing